To include your compound in the COVID-19 Resource Center, submit it here.

Transkaryotic regains rights to GA-II from AVE

TKTX said it reacquired commercial rights from partner Aventis

Read the full 91 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE